University of Hertfordshire Research Archive

        JavaScript is disabled for your browser. Some features of this site may not work without it.

        Browse

        All of UHRABy Issue DateAuthorsTitlesThis CollectionBy Issue DateAuthorsTitles

        Arkivum Files

        My Downloads
        View Item 
        • UHRA Home
        • University of Hertfordshire
        • Research publications
        • View Item
        • UHRA Home
        • University of Hertfordshire
        • Research publications
        • View Item

        BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates

        View/Open
        Final Published version (PDF, 1Mb)
        Author
        Kiguchi, Norikazu
        Ding, Huiping
        Cami-Kobeci, Gerta
        Sukhtankar, Devki D.
        Czoty, Paul W.
        DeLoid, Heather B.
        Hsu, Fang Chi
        Toll, Lawrence
        Husbands, Stephen M.
        Ko, Mei Chuan
        Attention
        2299/21352
        Abstract
        Background: The marked increase in mis-use of prescription opioids has greatly affected our society. One potential solution is to develop improved analgesics which have agonist action at both mu opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptors. BU10038 is a recently identified bifunctional MOP/NOP partial agonist. The aim of this study was to determine the functional profile of systemic or spinal delivery of BU10038 in primates after acute and chronic administration. Methods: A series of behavioural and physiological assays have been established specifically to reflect the therapeutic (analgesia) and side-effects (abuse potential, respiratory depression, itch, physical dependence, and tolerance) of opioid analgesics in rhesus monkeys. Results: After systemic administration, BU10038 (0.001–0.01 mg kg −1 ) dose-dependently produced long-lasting antinociceptive and antihypersensitive effects. Unlike the MOP agonist oxycodone, BU10038 lacked reinforcing effects (i.e. little or no abuse liability), and BU10038 did not compromise the physiological functions of primates including respiration, cardiovascular activities, and body temperature at antinociceptive doses and a 10–30-fold higher dose (0.01–0.1 mg kg −1 ). After intrathecal administration, BU10038 (3 μg) exerted morphine-comparable antinociception and antihypersensitivity without itch scratching responses. Unlike morphine, BU10038 did not cause the development of physical dependence and tolerance after repeated and chronic administration. Conclusions: These in vivo findings demonstrate the translational potential of bifunctional MOP/NOP receptor agonists such as BU10038 as a safe, non-addictive analgesic with fewer side-effects in primates. This study strongly supports that bifunctional MOP/NOP agonists may provide improved analgesics and an alternative solution for the ongoing prescription opioid crisis.
        Publication date
        2019-06-01
        Published in
        British Journal of Anaesthesia
        Published version
        https://doi.org/10.1016/j.bja.2018.10.065
        License
        Other
        Other links
        http://hdl.handle.net/2299/21352
        Metadata
        Show full item record

        Related items

        Showing items related by title, author, creator and subject.

        • Synthesis, biological evaluation, and SAR studies of 14β-phenylacetyl substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones derivatives : Ligands with mixed NOP and opioid receptor profile 

          Kumar, Vinod; Polgar, Willma E.; Cami-Kobeci, Gerta; Thomas, Mark P.; Khroyan, Taline V.; Toll, Lawrence; Husbands, Stephen M. (2018-09-19)
          A series of 14β-acyl substituted 17-cyclopropylmethyl-7,8-dihydronoroxymorphinone compounds has been synthesized and evaluated for affinity and efficacy for mu (MOP), kappa (KOP), and delta (DOP) opioid receptors and ...
        • Assessing the 2004-2018 fentanyl misusing issues reported to an international range of adverse reporting systems 

          Schifano, Fabrizio; Chiappini, Stephania; Corkery, John; Guirguis, Amira (2019-02-01)
          Objective: A recent, global, increase in the use of opioids including the prescribing, highly potent, fentanyl has been recorded. Due its current popularity and the potential lethal consequences of its intake, we aimed ...
        • Novel Synthetic Opioids (NSO) Use in Opioid Dependents Entering Detoxification Treatment 

          Specka, Michael; Kuhlmann, Thomas; Bonnet, Udo; Sawazki, Jürgen; Schaaf, Luzia; Kühnhold, Stefan; Steinert, Renate; Grigoleit, Torsten; Eich, Helmut; Zeiske, Benita; Niedersteberg, Antje; Steiner, Katharina; Schifano, Fabrizio; Scherbaum, Norbert (2022-06-01)
          Introduction: Over the last decade, the use of New/Novel Synthetic Opioids (NSO) has emerged as an increasing problem, and especially so in the USA. However, only little is known about the prevalence and history of NSO use ...
        Keep in touch

        © 2019 University of Hertfordshire

        I want to...

        • Apply for a course
        • Download a Prospectus
        • Find a job at the University
        • Make a complaint
        • Contact the Press Office

        Go to...

        • Accommodation booking
        • Your student record
        • Bayfordbury
        • KASPAR
        • UH Arts

        The small print

        • Terms of use
        • Privacy and cookies
        • Criminal Finances Act 2017
        • Modern Slavery Act 2015
        • Sitemap

        Find/Contact us

        • T: +44 (0)1707 284000
        • E: ask@herts.ac.uk
        • Where to find us
        • Parking
        • hr
        • qaa
        • stonewall
        • AMBA
        • ECU Race Charter
        • disability confident
        • AthenaSwan